<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800277</url>
  </required_header>
  <id_info>
    <org_study_id>GASTRO-Phenulin (2016-317)</org_study_id>
    <nct_id>NCT03800277</nct_id>
  </id_info>
  <brief_title>Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health</brief_title>
  <acronym>Phenulin</acronym>
  <official_title>Effect of Prebiotic Supplementation on Metabolic Endotoxemia and Modulation of the Gut Microbiota: Double-blind, Controlled and Randomized Parallel Clinical Study of the Efficacy and Synergistical Effect of Cranberry Polyphenols and Inulin From Agaves</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Agriculture, Fisheries and Food, Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of economic development, innovation and export trade, Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fruits d'Or, Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diana Food, Symrise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrium Innovations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NutriAgaves, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The growing prevalence of obesity and type 2 diabetes (T2D) is a major public health problem.
      Recent studies have clearly established that the gut microbiota plays a key role in the
      investigator's propensity to develop obesity and associated metabolic health disorders. The
      gut microbiota compositions plays a decisive role in glucose metabolism and the chronic
      inflammatory state associated with insulin resistance. Consuming prebiotic rich diet,
      including polyphenol and inulin rich food could help modulate favorably the gut microbiota
      which could lead to a reduction of endotoxemia and beneficial metabolic health effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is now recognized that overweight individuals have altered microbiota which could lead to
      intestinal barrier defects and chronic inflammation disorders. Polyphenols such as
      Proanthocyanidins may modulate the gut microbiota thereby providing beneficial effects on
      metabolic health. Inulin is a well known prebiotic that could stimulate growth of favorable
      bacteria in the gut.

      The overall goal is to determine the efficacy and synergy of a supplement of polyphenols from
      cranberry extract with or without a supplement of inulin from agaves to reduce chronic
      inflammation and endotoxemia and to improve glucose metabolism and insulin sensitivity by
      modulating microbiota of overweight human subjects with metabolic syndrome symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in metabolic endotoxemia: Measure concentration of Lipopolysaccharides (LPS) and Lipopolysaccharide Binding Protein (LBP) in plasma</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on variation in plasma concentration of LPS and LBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal permeability: Measure concentration of zonulin in plasma</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on plasma concentration of zonulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation state of the tissue: Measure concentration of calprotectin and lactoferrin in feces</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on fecal calprotectin and lactoferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systemic inflammation: Measure concentration of inflammation biomarkers in the serum</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on chronic inflammation (serum concentration of hsCRP, Il-6, TNF-alpha, IL-1 beta, IL-23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose serum concentration</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on serum concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin and C-peptide serum concentration</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>effect of the supplements on serum concentration of insulin and C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota diversity: growth of Akkermancia muciniphila, Lactobacillus, Prevotella, Bifdobacterium and inhibition of Clostridium perfringens, C. difficile, Bacteroides spp.)</measure>
    <time_frame>At the beginning and the end of treatment (10 weeks)</time_frame>
    <description>Global variation of the fecal microbiota and gut microbiota profiling</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Endotoxemia</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Cranberry and Agaves</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cranberry and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Agaves</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (2 capsules) + Agaves powder (1 single-dose packet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 capsules) + Placebo powder (1 single-dose packet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cranberry</intervention_name>
    <description>Supplementation of polyphenols from cranberry extract</description>
    <arm_group_label>Cranberry and Agaves</arm_group_label>
    <arm_group_label>Cranberry and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Agaves</intervention_name>
    <description>Supplementation of inulin from Agaves powder</description>
    <arm_group_label>Cranberry and Agaves</arm_group_label>
    <arm_group_label>Placebo and Agaves</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Supplementation with placebo</description>
    <arm_group_label>Cranberry and placebo</arm_group_label>
    <arm_group_label>Placebo and Agaves</arm_group_label>
    <arm_group_label>Placebo and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight (BMI 25-39.9 kg/m2)

          -  fasting glucose 5.6 - 6.9 mmol/L

          -  fasting insulin over 60 pmol/L

          -  hsCRP 1-10 mg/L

          -  at least one of the following criteria: waist circumference ≥ 80 cm (women) and ≥94 cm
             (men); Tg ≥ 1.7 mmol/L; blood pressure ≥ 130/85 mmHg; HDL &lt; 0,9 mmol/L

          -  non-smoking

          -  eating fruits and vegetables less then 5 portions/day

        Exclusion Criteria:

          -  chronic disease

          -  taking drugs or natural health products that could affect glucose or lipid metabolism

          -  taking anti-inflammatory, antiacids

          -  taking pre or probiotics

          -  inflammatory bowel disease

          -  antibiotics in the past 3 months

          -  allergy or intolerance to cranberries or agaves

          -  Major surgery in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Jacques, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of nutrition and functional foods, Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Desjardins, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of nutrition and functional foods, Laval University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Marois, M.Sc</last_name>
    <phone>418-656-2131</phone>
    <phone_ext>5764</phone_ext>
    <email>julie.marois@fsaa.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of nutrition and functional foods, Laval University</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Marois, M.Sc</last_name>
      <phone>418-656-2131</phone>
      <phone_ext>5764</phone_ext>
      <email>julie.marois@fsaa.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Hélène Jacques, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Desjardins, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Marette, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Roy, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Couture, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Helene Jacques</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

